InterPAD - DETAILS

thalidomide, 50-35-1, Thalomid, 2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione, Contergan, Distaval, Pantosediv, Softenon, (+/-)-THALIDOMIDE, Kevadon, Theophilcholine, Algosediv, Corronarobetin, Ectiluran, Enterosediv, Gastrinide, Nerosedyn, Neurosedin, Neurosedym, Noctosediv, Profarmil, Psycholiquid, Psychotablets, Quietoplex, Sandormin, Sedisperil, Shinnibrol, Telargean, Thalinette, Valgraine, Asmadion, Asmaval, Bonbrain, Calmore, Calmorex, Glutanon, Grippex, Hippuzon, Imidene, Neosedyn, Neosydyn, Neufatin, Neurodyn, Nevrodyn, Noxodyn, Quetimid, Sedimide, Sedoval, Sleepan, Softenil, Talargan, Talimol, Talismol, Telagan, Tensival, Yodomin, Glupan, Isomin, Nibrol, Pangul, Sedin, Slipro, Thalin, Valgis, N-Phthaloylglutamimide, Predni-Sediv, Imida-lab, Sedalis sedi-lab, N-Phthalylglutamic acid imide, Neaufatin, Asidon 3, Pro-ban M, 3-Phthalimidoglutarimide, Shin-naito S, Imidan (peyta), Neurosedyn, Ulcerfen, Talidomida, alpha-Phthalimidoglutarimide, Distaxal, Distoval, Kedavon, Thalomide, Thaled, (+-)-Thalidomide, K-17, 2,6-Dioxo-3-phthalimidopiperidine, Thalidomide Celgene, NSC-66847, Thalidomidum, Bonbrrin, Pharmion, Talidomide, Telargan, Celgene, Pro-Bam M, Sedalis, N-(2,6-Dioxo-3-piperidyl)phthalimide, alpha-N-Phthalylglutaramide, Glutarimide, 2-phthalimido-, N-Phthalyl-glutaminsaeure-imid, alpha-(N-Phthalimido)glutarimide, Synovir, Myrin, K 17, Talidomida [INN-Spanish], Thalidomidum [INN-Latin], .alpha.-Phthalimidoglutarimide, 1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline, E-217, HSDB 3586, 2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-, UNII-4Z8R6ORS6L, Phthalimide, N-(2,6-dioxo-3-piperidyl)-, EINECS 200-031-1, 4Z8R6ORS6L, .alpha.-N-Phthalylglutaramide, NSC 527179, NSC-527179, BRN 0030233, CCRIS 8148, DTXSID9022524, AI3-50606, (+-)-N-(2,6-Dioxo-3-piperidyl)phthalimide, .alpha.-(N-Phthalimido)glutarimide, NSC66847, 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione, MFCD00153873, CHEMBL468, Thalidomide (soluble form), ENMD 0995, DTXCID402524, CHEBI:74947, (+/-)-N-(2,6-dioxo-3-piperidyl)phthalimide, 2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione, Thalidomide [USAN:USP:INN:BAN:JAN], NCGC00015989-09, Talidomide [DCIT], 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-, (+-)-, Talidomida (INN-Spanish), Thalidomidum (INN-Latin), THALIDOMIDE (MART.), THALIDOMIDE [MART.], THALIDOMIDE (USP-RS), THALIDOMIDE [USP-RS], 1012310-87-0, Thalidomine USP26, 2-(2,6-Dioxo-piperidin-3-yl)-isoindole-1,3-dione, Talizer, THALIDOMIDE (USP MONOGRAPH), THALIDOMIDE [USP MONOGRAPH], Phthalimide,6-dioxo-3-piperidyl)-, WLN: T56 BVNVJ C- DT6VMVTJ, 1H-ISOINDOLE-1,3(2H)-DIONE, 2-(2,6-DIOXO-3-PIPERIDINYL)-, (+/-)-, Thalidomide (USAN:USP:INN:BAN:JAN), Thalomid (TM), Thalomid (TN), Thalidomide Pharmion, Thaled (TN), N-Phthalyl-glutaminsaeure-imid [German], N-Phthalimidoglutamic acid imide, 1H-Isoindole-1, 2-(2,6-dioxo-3-piperidinyl)-, SR-01000076184, Talinol, Thalidomide (JAN/USP/INN), NSC-91729, NSC-91730, (y)-Thalidomide, Thalidomide,(S), CAS-50-35-1, (?)-Thalidomide, 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione, Prestwick_463, Sedoval K-17, (A+/-)-Thalidomide, N-(2,6-dioxo-3-piperidinyl)phthalimide, THALIDOMIDE [MI], (+/-)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, Prestwick0_000192, Prestwick1_000192, Prestwick2_000192, Prestwick3_000192, Spectrum2_000707, Spectrum3_001715, Spectrum4_001087, Spectrum5_001791, THALIDOMIDE [INN], THALIDOMIDE [JAN], (.+/-.)-Thalidomide, THALIDOMIDE [HSDB], THALIDOMIDE [USAN], UPCMLD-DP139, THALIDOMIDE [VANDF], Thalomid (TN) (Celgene), SCHEMBL7581, NCIOpen2_003188, Lopac0_001224, BSPBio_000143, BSPBio_001156, BSPBio_003330, KBioGR_000496, KBioGR_001474, KBioGR_002322, KBioSS_000496, KBioSS_002324, THALIDOMIDE [WHO-DD], 2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione, MLS000069353, DivK1c_000051, SPECTRUM1503607, SPBio_000893, SPBio_002064, 2-PHTHALIMIDOGLUTARIMIDE, THALIDOMIDE [EMA EPAR], BPBio1_000159, CHEBI:9513, GTPL7327, SCHEMBL15197560, UPCMLD-DP139:001, HMS500C13, KBio1_000051, KBio2_000496, KBio2_002322, KBio2_003064, KBio2_004890, KBio2_005632, KBio2_007458, KBio3_000911, KBio3_000912, KBio3_002550, KBio3_002802, L04AX02, THALIDOMIDE [ORANGE BOOK], cMAP_000022, NINDS_000051, Bio1_000387, Bio1_000876, Bio1_001365, Bio2_000418, Bio2_000898, HMS1362J17, HMS1568H05, HMS1792J17, HMS1922E12, HMS1990J17, HMS2090O05, HMS2093G15, HMS2095H05, HMS2234C07, HMS3259C22, HMS3263F10, HMS3266F13, HMS3373E06, HMS3373G15, HMS3403J17, HMS3414F19, HMS3654A20, HMS3678F19, HMS3712H05, HMS3884I05, Pharmakon1600-01503607, BCP19772, NSC91729, NSC91730, 2, 6-Dioxo-3-phthalimidopiperidine, Tox21_110275, Tox21_300580, Tox21_501224, AC-917, BBL023439, BDBM50070114, CCG-39878, NSC527179, NSC758479, STL356025, ( inverted question mark)-Thalidomide, AKOS009529198, Tox21_110275_1, CS-1084, DB01041, LP01224, NC00600, NSC-758479, SDCCGSBI-0051191.P004, (+/-)-Thalidomide, >=98%, powder, IDI1_000051, IDI1_002173, NCGC00015989-03, NCGC00015989-04, NCGC00015989-05, NCGC00015989-06, NCGC00015989-07, NCGC00015989-08, NCGC00015989-10, NCGC00015989-11, NCGC00015989-12, NCGC00015989-13, NCGC00015989-14, NCGC00015989-16, NCGC00015989-17, NCGC00015989-29, NCGC00024708-02, NCGC00024708-03, NCGC00024708-04, NCGC00024708-05, NCGC00024708-06, NCGC00024708-07, NCGC00024708-08, NCGC00024708-09, NCGC00024708-10, NCGC00024708-11, NCGC00254343-01, NCGC00261909-01, AS-12367, BP-30256, BT164465, HY-14658, NCI60_023904, SMR000058524, SY052614, WLN: T56 BVNVJ C- DT6VMVTJ -D, WLN: T56 BVNVJ C- DT6VMVTJ -L, SBI-0051191.P003, DB-051759, Phthalimide,6-dioxo-3-piperidyl)-, (+)-, Phthalimide,6-dioxo-3-piperidyl)-, (-)-, AB00052362, EU-0101224, NS00009590, S1193, SW196678-4, T2524, EN300-60005, Phthalimide,6-dioxo-3-piperidyl)-, D-(+)-, Phthalimide,6-dioxo-3-piperidyl)-, L-(-)-, C07910, D00754, AB00052362-11, AB00052362-12, AB00052362-13, AB00052362_14, AB00052362_15, Q203174, SR-01000076184-1, SR-01000076184-3, SR-01000076184-5, SR-01000076184-8, Thalidomide N-(2,6-Dioxopiperidin-3-yl)phthalimide, W-105969, BRD-A93255169-001-04-4, BRD-A93255169-001-06-9, BRD-A93255169-001-24-2, Z905162656, 1H-Isoindole-1, 2-(2,6-dioxo-3-piperidinyl)-, (R)-, 1H-Isoindole-1, 2-(2,6-dioxo-3-piperidinyl)-, (S)-, 2-((3RS)-2,6-Dioxopiperidin-3-yl)isoindoline-1,3-dione, 2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione #, rac-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione, [(R,S)-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, Thalidomide, United States Pharmacopeia (USP) Reference Standard, ( inverted question mark)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, 2-(6-hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione

Name	Thalidomide
PubChem CID	5426
Molecular Weight	258.23g/mol
Synonyms	thalidomide, 50-35-1, Thalomid, 2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione, Contergan, Distaval, Pantosediv, Softenon, (+/-)-THALIDOMIDE, Kevadon, Theophilcholine, Algosediv, Corronarobetin, Ectiluran, Enterosediv, Gastrinide, Nerosedyn, Neurosedin, Neurosedym, Noctosediv, Profarmil, Psycholiquid, Psychotablets, Quietoplex, Sandormin, Sedisperil, Shinnibrol, Telargean, Thalinette, Valgraine, Asmadion, Asmaval, Bonbrain, Calmore, Calmorex, Glutanon, Grippex, Hippuzon, Imidene, Neosedyn, Neosydyn, Neufatin, Neurodyn, Nevrodyn, Noxodyn, Quetimid, Sedimide, Sedoval, Sleepan, Softenil, Talargan, Talimol, Talismol, Telagan, Tensival, Yodomin, Glupan, Isomin, Nibrol, Pangul, Sedin, Slipro, Thalin, Valgis, N-Phthaloylglutamimide, Predni-Sediv, Imida-lab, Sedalis sedi-lab, N-Phthalylglutamic acid imide, Neaufatin, Asidon 3, Pro-ban M, 3-Phthalimidoglutarimide, Shin-naito S, Imidan (peyta), Neurosedyn, Ulcerfen, Talidomida, alpha-Phthalimidoglutarimide, Distaxal, Distoval, Kedavon, Thalomide, Thaled, (+-)-Thalidomide, K-17, 2,6-Dioxo-3-phthalimidopiperidine, Thalidomide Celgene, NSC-66847, Thalidomidum, Bonbrrin, Pharmion, Talidomide, Telargan, Celgene, Pro-Bam M, Sedalis, N-(2,6-Dioxo-3-piperidyl)phthalimide, alpha-N-Phthalylglutaramide, Glutarimide, 2-phthalimido-, N-Phthalyl-glutaminsaeure-imid, alpha-(N-Phthalimido)glutarimide, Synovir, Myrin, K 17, Talidomida [INN-Spanish], Thalidomidum [INN-Latin], .alpha.-Phthalimidoglutarimide, 1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline, E-217, HSDB 3586, 2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-, UNII-4Z8R6ORS6L, Phthalimide, N-(2,6-dioxo-3-piperidyl)-, EINECS 200-031-1, 4Z8R6ORS6L, .alpha.-N-Phthalylglutaramide, NSC 527179, NSC-527179, BRN 0030233, CCRIS 8148, DTXSID9022524, AI3-50606, (+-)-N-(2,6-Dioxo-3-piperidyl)phthalimide, .alpha.-(N-Phthalimido)glutarimide, NSC66847, 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione, MFCD00153873, CHEMBL468, Thalidomide (soluble form), ENMD 0995, DTXCID402524, CHEBI:74947, (+/-)-N-(2,6-dioxo-3-piperidyl)phthalimide, 2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione, Thalidomide [USAN:USP:INN:BAN:JAN], NCGC00015989-09, Talidomide [DCIT], 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-, (+-)-, Talidomida (INN-Spanish), Thalidomidum (INN-Latin), THALIDOMIDE (MART.), THALIDOMIDE [MART.], THALIDOMIDE (USP-RS), THALIDOMIDE [USP-RS], 1012310-87-0, Thalidomine USP26, 2-(2,6-Dioxo-piperidin-3-yl)-isoindole-1,3-dione, Talizer, THALIDOMIDE (USP MONOGRAPH), THALIDOMIDE [USP MONOGRAPH], Phthalimide,6-dioxo-3-piperidyl)-, WLN: T56 BVNVJ C- DT6VMVTJ, 1H-ISOINDOLE-1,3(2H)-DIONE, 2-(2,6-DIOXO-3-PIPERIDINYL)-, (+/-)-, Thalidomide (USAN:USP:INN:BAN:JAN), Thalomid (TM), Thalomid (TN), Thalidomide Pharmion, Thaled (TN), N-Phthalyl-glutaminsaeure-imid [German], N-Phthalimidoglutamic acid imide, 1H-Isoindole-1, 2-(2,6-dioxo-3-piperidinyl)-, SR-01000076184, Talinol, Thalidomide (JAN/USP/INN), NSC-91729, NSC-91730, (y)-Thalidomide, Thalidomide,(S), CAS-50-35-1, (?)-Thalidomide, 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione, Prestwick_463, Sedoval K-17, (A+/-)-Thalidomide, N-(2,6-dioxo-3-piperidinyl)phthalimide, THALIDOMIDE [MI], (+/-)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, Prestwick0_000192, Prestwick1_000192, Prestwick2_000192, Prestwick3_000192, Spectrum2_000707, Spectrum3_001715, Spectrum4_001087, Spectrum5_001791, THALIDOMIDE [INN], THALIDOMIDE [JAN], (.+/-.)-Thalidomide, THALIDOMIDE [HSDB], THALIDOMIDE [USAN], UPCMLD-DP139, THALIDOMIDE [VANDF], Thalomid (TN) (Celgene), SCHEMBL7581, NCIOpen2_003188, Lopac0_001224, BSPBio_000143, BSPBio_001156, BSPBio_003330, KBioGR_000496, KBioGR_001474, KBioGR_002322, KBioSS_000496, KBioSS_002324, THALIDOMIDE [WHO-DD], 2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione, MLS000069353, DivK1c_000051, SPECTRUM1503607, SPBio_000893, SPBio_002064, 2-PHTHALIMIDOGLUTARIMIDE, THALIDOMIDE [EMA EPAR], BPBio1_000159, CHEBI:9513, GTPL7327, SCHEMBL15197560, UPCMLD-DP139:001, HMS500C13, KBio1_000051, KBio2_000496, KBio2_002322, KBio2_003064, KBio2_004890, KBio2_005632, KBio2_007458, KBio3_000911, KBio3_000912, KBio3_002550, KBio3_002802, L04AX02, THALIDOMIDE [ORANGE BOOK], cMAP_000022, NINDS_000051, Bio1_000387, Bio1_000876, Bio1_001365, Bio2_000418, Bio2_000898, HMS1362J17, HMS1568H05, HMS1792J17, HMS1922E12, HMS1990J17, HMS2090O05, HMS2093G15, HMS2095H05, HMS2234C07, HMS3259C22, HMS3263F10, HMS3266F13, HMS3373E06, HMS3373G15, HMS3403J17, HMS3414F19, HMS3654A20, HMS3678F19, HMS3712H05, HMS3884I05, Pharmakon1600-01503607, BCP19772, NSC91729, NSC91730, 2, 6-Dioxo-3-phthalimidopiperidine, Tox21_110275, Tox21_300580, Tox21_501224, AC-917, BBL023439, BDBM50070114, CCG-39878, NSC527179, NSC758479, STL356025, ( inverted question mark)-Thalidomide, AKOS009529198, Tox21_110275_1, CS-1084, DB01041, LP01224, NC00600, NSC-758479, SDCCGSBI-0051191.P004, (+/-)-Thalidomide, >=98%, powder, IDI1_000051, IDI1_002173, NCGC00015989-03, NCGC00015989-04, NCGC00015989-05, NCGC00015989-06, NCGC00015989-07, NCGC00015989-08, NCGC00015989-10, NCGC00015989-11, NCGC00015989-12, NCGC00015989-13, NCGC00015989-14, NCGC00015989-16, NCGC00015989-17, NCGC00015989-29, NCGC00024708-02, NCGC00024708-03, NCGC00024708-04, NCGC00024708-05, NCGC00024708-06, NCGC00024708-07, NCGC00024708-08, NCGC00024708-09, NCGC00024708-10, NCGC00024708-11, NCGC00254343-01, NCGC00261909-01, AS-12367, BP-30256, BT164465, HY-14658, NCI60_023904, SMR000058524, SY052614, WLN: T56 BVNVJ C- DT6VMVTJ -D, WLN: T56 BVNVJ C- DT6VMVTJ -L, SBI-0051191.P003, DB-051759, Phthalimide,6-dioxo-3-piperidyl)-, (+)-, Phthalimide,6-dioxo-3-piperidyl)-, (-)-, AB00052362, EU-0101224, NS00009590, S1193, SW196678-4, T2524, EN300-60005, Phthalimide,6-dioxo-3-piperidyl)-, D-(+)-, Phthalimide,6-dioxo-3-piperidyl)-, L-(-)-, C07910, D00754, AB00052362-11, AB00052362-12, AB00052362-13, AB00052362_14, AB00052362_15, Q203174, SR-01000076184-1, SR-01000076184-3, SR-01000076184-5, SR-01000076184-8, Thalidomide N-(2,6-Dioxopiperidin-3-yl)phthalimide, W-105969, BRD-A93255169-001-04-4, BRD-A93255169-001-06-9, BRD-A93255169-001-24-2, Z905162656, 1H-Isoindole-1, 2-(2,6-dioxo-3-piperidinyl)-, (R)-, 1H-Isoindole-1, 2-(2,6-dioxo-3-piperidinyl)-, (S)-, 2-((3RS)-2,6-Dioxopiperidin-3-yl)isoindoline-1,3-dione, 2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione #, rac-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione, [(R,S)-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, Thalidomide, United States Pharmacopeia (USP) Reference Standard, ( inverted question mark)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, 2-(6-hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione
Drug Type	Small molecule
Formula	C₁₃H₁₀N₂O₄
SMILES	C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
InChI	1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)
InChIKey	UEJJHQNACJXSKW-UHFFFAOYSA-N
CAS Number	50-35-1
ChEMBL ID	CHEMBL468
ChEBI ID	CHEBI:74947
TTD ID	D0U7GK
Drug Bank ID	DB01041
KEGG ID	C07910
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Curcumin, Thalidomide
Partner Name	Curcumin
Disease Info	[ICD-11: 2A60.Z]	Acute myeloid leukemia		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BCL-xL	hsa598
Gene Regulation	Down-regulation	Expression	STAT3	hsa6774
In Vitro Model	KG-1a	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_1824
In Vitro Model	U-937	Adult acute monocytic leukemia	Homo sapiens (Human)	CVCL_0007
Result	Our findings suggested that down-regulation of STAT3 and BCL-XL mRNA expression in response to CUR and THAL treatment lead to inhibition of cell growth and induction of apoptosis.